Published on 7 Nov 2023 on GuruFocus.com via Yahoo Finance

Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) reported a net loss of approximately $10.1 million for Q3 2023, compared to a net loss of approximately $8.8 million for the same period in 2022.Operating expenses increased by $1.3 million to approximately $9.5 million for Q3 2023, compared to $8.2 million in Q3 2022.As of September 30, 2023, the company has $28.7 million of cash, cash equivalents, and investments on hand.CRBP is making progress with its diversified portfolio, including CRB-701, CRB-601, and CRB-913.

Warning! GuruFocus has detected 2 Warning Signs with CRBP.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its Q3 2023 financial results on November 7, 2023. The company reported a net loss of approximately $10.1 million, or a net loss per diluted share of $2.27, for the three months ended September 30, 2023. This is compared to a net loss of approximately $8.8 million, or a net loss per diluted share of $2.11, for the same period in 2022.